T2 Biosystems, Inc.

OTCPK:TTOO Rapport sur les actions

Capitalisation boursière : US$84.1k

T2 Biosystems Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Craig Jalbert

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur général1.1yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction4.3yrs
Durée moyenne du mandat des membres du conseil d'administration4.1yrs

Mises à jour récentes de la gestion

Recent updates

Article d’analyse • Apr 18

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

T2 Biosystems, Inc.'s ( NASDAQ:TTOO ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong buy...
Seeking Alpha • Oct 13

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems (NASDAQ:TTOO) said on Thursday it had planned to to complete development of, and commercialize, a diagnostic test to detect early Lyme disease. The company expects to begin marketing and sales in the United States as a Laboratory Developed Test (LDT) in 2023. "We believe the T2Lyme Panel will potentially allow clinicians to ensure patients receive appropriate therapy faster, and prevent the negative impact of a delay in delivery of appropriate therapy and the overuse of antibiotics,” said John Sperzel, CEO of T2Biosystems. The molecular diagnostic test, T2Lyme panel, is designed to run on the FDA-cleared T2Dx Instrument and to detect Borrelia burgdorferi, the bacteria that causes Lyme disease. Lyme disease is a bacterial infection caused by the genes Borrelia and is transmitted to humans through the bite of infected ticks. About 476,000 Americans may get Lyme disease each year in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).
Seeking Alpha • Sep 29

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

Biomedical Advanced Research and Development Authority (or BARDA) is providing T2 Biosystems (NASDAQ:TTOO) an additional $3.7M in funding for the multiple-year cost-share contract. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The total potential BARDA funding if all contract options are exercised is $62M, reflecting a reduction in the scope of work under contract option 3. "We are pleased to advance the U.S. clinical trials for the T2Resistance Panel and T2Biothreat Panel, in collaboration with BARDA, and subsequently file submissions with FDA for U.S. regulatory clearance. These new products will expand the test menu on our T2Dx Instrument and have the potential to reduce the threat of antimicrobial resistance and protect the nation from biothreat pathogens.” stated John Sperzel, Chairman and CEO.
Seeking Alpha • Sep 22

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems (NASDAQ:TTOO) on Thursday said it had entered into a distribution agreement in the Baltic region for the sale of its products. Shares of the micro-cap diagnostics company jumped 17.3% to $0.10 after hours. It is worth noting that TTOO stock had earlier closed 11.8% lower to notch its eight straight session in the red. As per the agreement with the distributor, TTOO can sell products such as its T2Bacteria Panel, which can identify sepsis-causing bacteria, and its T2Candida Panel, which can detect fungal pathogens. "We are committed to expanding our commercialization worldwide and these new distribution agreements provide access to important markets in Lithuania, Latvia, and Estonia,” TTOO CEO John Sperzel said in a statement.
Seeking Alpha • Aug 26

T2 Biosystems' Survival Riddle

Summary T2's ongoing survival is a marvel to behold. T2's products fill key niches but have yet to show any viable commercial appeal. The elephant in the room for T2 shareholders is whether it will ever participate in any upside that may reside in its intellectual property. T2 Biosystems (TTOO) is a bygone favorite of mine that has bumped along on the fringes. I last discussed it in 08/2020's "COVID-19 Opportunity Knocks, T2 Answers". At the time, T2 was hoping to use interest in its rapid COVID diagnostics to place its T2Dx diagnostic device in hospitals. T2's strategy has been successful, but at an insufficient scale to turn it around. Placing devices is an important focus of T2's business development strategy. During T2's Q2 2022 earnings call (the "Call"), CEO Sperzel advised that its strategy was playing out as planned. It was gradually transitioning instruments that had been used for processing T2SARS-CoV-2 panels to use for sepsis testing. As a result, T2 has been experiencing an expected decline in COVID testing. [It] view[s] this development as a positive because it allows [it] to convert COVID-driven instruments to sepsis testing. As a reminder, [it] sold 47 T2Dx instruments to hospital microbiology labs during 2020, initially for COVID-19 testing, with the expectation that approximately 80% would convert to ... sepsis test panels over time. Selling instruments is an important driver of revenues for T2. Once an instrument is placed, it generates ongoing revenues. During the Call Sperzel explained: From an instrument pull-through perspective, in the United States, we achieved annualized sepsis tests utilization of $106,000 for legacy instruments. We continue to believe that annualized US sepsis test utilization will reach $200,000 per instrument and we have a number of customers that have already surpassed that target. We believe there is a significant market opportunity for our products, and we're excited to expand our presence in new and existing customers. During the Call, he also advised that T2's installed base of instruments includes a total of 155, 94 in the US and 61 internationally. When you consider that the instrument was FDA approved in 09/2014, this is a discouraging total. T2 has gone from troubled to extremely troubled, but somehow it keeps on ticking. My first (11/2019) T2 article, "T2: Navigating The Danger Zone", presented a cautiously optimistic view of this company. T2 had snagged its FDA approval back in 2014 for its instrument, but was, and still is, wallowing in the danger zone as it works to commercialize its T2Dx diagnostic device. It's hard to believe that T2, which currently (08/25/2022) trades for ~$0.13 went public in 08/2014 at ~$11.00 and subsequently traded >$20.00. Cheap does not a bargain make. T2's current down and nearly out share price reflects some very real problems that are dogging this company. Its rapid diagnostic products are quite attractive from any patient's point of view. The problem is that T2 has yet to figure out how to market them in commercially sufficient quantities to meet its expenses, much less earn a profit. T2's long-fought efforts for commercial viability have decimated the company's shares. It is struggling to maintain its NASDAQ listing. It currently anticipates a reverse stock split of somewhere between 1-for-10 and 1-for-50. If it would elect the 1 for 50 ratio, a shareholder who currently owns 50 shares trading at $0.13 would instead own 1 share worth $6.50; if it elects the 1 for 10 ratio, then shareholder would own 5 shares worth $1.30, still aggregating $6.50. T2 has an outstanding debt financing, originally for $40 million, with CRG. This financing has long been a concern of mine as I discuss at length in "T2: A Catch With A Catch". This concern is only exacerbated by T2's ongoing losses. The CRG loan is secured by a lien on substantially all of T2's assets, including its intellectual property. The loan requires T2 to maintain a minimum cash balance of $5 million along with other covenants. It is prepayable. In its latest 10-K, T2 advises: ...[It] intend[s] to continue to evaluate options to refinance the Term Loan Agreement, which becomes due on December 30, 2023. There can be no assurances that we will be able to refinance on terms favorable or at all. The amounts involved in any such transactions, individually or in the aggregate, may be material. Because the loan and its covenants are so important, T2 advised during the Call that it was then in compliance with all its loan covenants. As I recall from past review, this is a common bit of assurance that T2 has so far been able to provide during its quarterly earnings calls. T2 has a bevy of highly attractive products which have not proven financially viable. The issue with T2 that is especially frustrating relates to the extreme appeal of its products from a patient's point of view. Its current products are shown on its Q2 2022 presentation slide below: seekingalpha.com T2's rapid results are a godsend for patients who need to get a health screening, but who can ill afford long delays that are prevalent in the industry.

PDG

Craig Jalbert (63 yo)

1.1yrs
Titularisation

Mr. Craig R. Jalbert, CIRA, is CEO, President, Corporate Treasurer, Corporate Secretary & Director of T2 Biosystems, Inc. from April 3, 2025. He is Director of CohBar, Inc. from November 6, 2023. He served...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Craig Jalbert
CEO, President1.1yrspas de donnéespas de données
Kelley Morgan
Chief People Officer12.2yrspas de donnéespas de données
Brett Giffin
Chief Commercial Officer4.5yrspas de donnéespas de données
Roger Smith
Senior Vice President of Science Research & Development4.2yrspas de donnéespas de données
4.3yrs
Durée moyenne de l'emploi
61.5yo
Âge moyen

Gestion expérimentée: L'équipe de direction de TTOO est considérée comme expérimentée (ancienneté moyenne 4.3 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Craig Jalbert
CEO, President1.1yrspas de donnéespas de données
Eric Rosenberg
Member of Clinical Advisory Board15yrspas de donnéespas de données
Louis Rice
Member of Clinical Advisory Board15yrspas de donnéespas de données
Michael Rybak
Member of Scientific Advisory Board4.1yrspas de donnéespas de données
James Snyder
Member of Scientific Advisory Board4.1yrspas de donnéespas de données
Ninfa Saunders
Independent Director5.9yrsUS$50.00k0.00026%
$ 0.2
Thomas Walsh
Member of Scientific Advisory Board4.1yrspas de donnéespas de données
Peter Pappas
Member of Clinical Advisory Board15yrspas de donnéespas de données
Michael Pfaller
Member of Clinical Advisory Board8.8yrsUS$1.10mpas de données
Sean Zhang
Member of Scientific Advisory Board4.1yrspas de donnéespas de données
Denise Uettwiller-Geiger
Member of Scientific Advisory Board4.1yrspas de donnéespas de données
George Pankey
Member of Scientific Advisory Board4.1yrspas de donnéespas de données
4.1yrs
Durée moyenne de l'emploi
73yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TTOO sont considérés comme expérimentés (ancienneté moyenne 4.1 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/21 03:52
Cours de l'action en fin de journée2026/05/18 00:00
Les revenus2024/09/30
Revenus annuels2023/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

T2 Biosystems, Inc. est couverte par 10 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Benjamin HaynorAlliance Global Partners
Paul KnightBrean Capital Historical (Janney Montgomery)
Karen KoskiBTIG